Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells

Cancer Gene Therapy

Volumn 17, Issue 9, 2010, Pages 599-613

  Nalla, A K ^a   Gorantla, B ^a   Gondi, C S ^a   Lakka, S S ^a   Rao, J S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

apoptosis; cathepsin; MMP 9; prostate cancer; RNAi; uPAR

Indexed keywords

CASPASE 7; CASPASE 8; CATHEPSIN B; FAS ANTIGEN; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; UROKINASE RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; NICK END LABELING; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROSTATE CANCER; WOUND HEALING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CATHEPSIN B; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77955920079     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.16     Document Type: Article

References (63)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-1253.
3. Bianco Jr FJ, Wood Jr DP, Gomes de OJ, Nemeth JA, Beaman AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 2001; 49: 235-242.
4. Roth BJ. Prostate cancer chemotherapy: emerging from the shadows. J Clin Oncol 2005; 23: 3302-3303.
5. Chen AC, Petrylak DP. Complications of androgen-depriva-tion therapy in men with prostate cancer. Curr Urol Rep 2005; 6: 210-216.
6. Ferrero JM. Hormone resistant metastatic prostate cancer: analysis of two phase III clinical studies. Bull Cancer 2005; 92: 425-427.
7. Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005; 65: 8-12.
8. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 2000; 31: 578-583.
9. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM. Molecular interactions in cancer cell metastasis. Acta Histochem 2010; 112: 3-25.
10. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
11. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10: 39-49.
12. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-681.
13. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
14. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489-501.
15. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-136.
16. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684-1695.
17. Blasi F, Carmeliet P. uPAR: a versatile signalling orches-trator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
18. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307: 269-273.
19. Khasigov PZ, Podobed OV, Gracheva TS, Salbiev KD, Grachev SV, Berezov TT. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry (Mosc) 2003; 68: 711-717.
20. Freije JM, ez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-16773.
21. Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G et al. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 1993; 53: 165-169.
22. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-433.
23. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-744.
24. Mira E, Lacalle RA, Buesa JM, de Buitrago GG, Jimenez-Baranda S, Gomez-Mouton C et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004; 117: 1847-1857.
25. Tu C, Ortega-Cava CF, Chen G, Fernandes ND, Cavallo-Medved D, Sloane BF et al. Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res 2008; 68: 9147-9156.
26. Creemers LB, Hoeben KA, Jansen DC, Buttle DJ, Beertsen W, Everts V. Participation of intracellular cysteine protei-nases, in particular cathepsin B, in degradation of collagen in periosteal tissue explants. Matrix Biol 1998; 16: 575-584.
27. Yin LL, Chung CM, Chen J, Fok KL, Ng CP, Jia RR et al. A suppressor of multiple extracellular matrix-degrading proteases and cancer metastasis. J Cell Mol Med 2009; 13: 4034-4041.
28. Hwang JH, Lee SH, Lee KH, Lee KY, Kim H, Ryu JK et al. Cathepsin B is a target of Hedgehog signaling in pancreatic cancer. Cancer Lett 2009; 273: 266-272.
29. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002; 62: 2390-2397.
30. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
31. Frlan R, Gobec S. Inhibitors of cathepsin B. Curr Med Chem 2006; 13: 2309-2327.
32. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 17-25.
33. Arens N, Gandhari M, Bleyl U, Hildenbrand R. In vitro suppression of urokinase plasminogen activator in breast cancer cells\a comparison of two antisense strategies. Int J Oncol 2005; 26: 113-119.
34. D'Alessio S, Margheri F, Pucci M, Del Rosso A, Monia BP, Bologna M et al. Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 2004; 110: 125-133.
35. Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogen-esis. Oncogene 2003; 22: 5967-5975.
36. Margheri F, D'Alessio S, Serrati S, Pucci M, Annunziato F, Cosmi L et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 2005; 12: 702-714.
37. Gartel AL, Kandel ES. RNA interference in cancer. Biomol Eng 2006; 23: 17-34.
38. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004; 23: 8486-8496.
39. Lakka SS, Gondi CS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M et al. Synergistic down regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 2003; 63: 2454-2461.
40. Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO. Ionising radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer 2007; 43: 1214-1224.
41. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994; 218: 314-319.
42. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280: 36529-36540.
43. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP et al. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004; 64: 5311-5321.
44. Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G et al. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 1999; 35: 138-144.
45. Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Ther Targets 2000; 4: 609-633.
46. Lakka SS, Rajan M, Gondi CS, Yanamandra N, Chandrasekar N, Jasti SL et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002; 21: 8011-8019.
47. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007; 121: 2307-2316.
48. Gondi CS, Lakka SS, Dinh D, Olivero W, Gujrati M, Rao JS. Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 2004; 1: 165-176.
49. Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH et al. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol 2007; 31: 1039-1050.
50. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6: 764-775.
51. Mohr S, McCormick TS, Lapetina EG. Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059. Proc Natl Acad Sci USA 1998; 95: 5045-5050.
52. Woessmann W, Zwanzger D, Borkhardt A. ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent. Cell Biol Int 2004; 28: 403-410.
53. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20: 147-155.
54. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000; 275: 39435-39443.
55. Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 2008; 283: 1545-1552.
56. Gondi CS, Kandhukuri N, Kondraganti S, Gujrati M, Olivero WC, Dinh DH et al. RNA interference-mediated simultaneous down regulation of urokinase-type plasmino-gen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells. Mol Cancer Ther 2006; 5: 3197-3208.
57. Mo YY, Beck WT. DNA damage signals induction of fas ligand in tumor cells. Mol Pharmacol 1999; 55: 216-222.
58. Chetty C, Bhoopathi P, Lakka SS, Rao JS. MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. Oncogene 2007; 26: 7675-7683.
59. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS. Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-{kappa}B activity leading to apoptosis in breast tumors. Clin Cancer Res 2008; 14: 3617-3626.
60. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.
61. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
62. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2665-2672.
63. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.